Lv7
3480 积分 2021-10-11 加入
Efficacy and safety of telitacicept in patients with class III–V lupus nephritis: A real-world retrospective cohort study
5天前
已关闭
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
20天前
已完结
Chronic lymphocytic leukaemia: from genetics to treatment
20天前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
20天前
已完结
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study
22天前
已完结
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma
22天前
已完结
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
22天前
已完结
Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia
23天前
已完结
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib
23天前
已完结
Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor
23天前
已完结
皖公网安备34019202002308
